HUE028830T2 - Humán anti-B7RP1 semlegesítõ ellenanyagok - Google Patents

Humán anti-B7RP1 semlegesítõ ellenanyagok Download PDF

Info

Publication number
HUE028830T2
HUE028830T2 HUE06787719A HUE06787719A HUE028830T2 HU E028830 T2 HUE028830 T2 HU E028830T2 HU E06787719 A HUE06787719 A HU E06787719A HU E06787719 A HUE06787719 A HU E06787719A HU E028830 T2 HUE028830 T2 HU E028830T2
Authority
HU
Hungary
Prior art keywords
ser
val
leu
gly
thr
Prior art date
Application number
HUE06787719A
Other languages
English (en)
Inventor
Gerald Siu
Wenyan Shen
Steven Kiyoshi Yoshinaga
Haichun Huang
Original Assignee
Amgen Inc
Squibb & Sons Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Squibb & Sons Llc filed Critical Amgen Inc
Publication of HUE028830T2 publication Critical patent/HUE028830T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (13)

  1. ítóröadálmí igéöypnstnk I> Izolált ellenanyag, amely specifikusa« kítóálk B7RFÍ-tóz, ató! az «Issasyag ol^aa sÄzISacoi; tartaltnaz, amely SEQ I© MO;: 27 wái. stekvmeiäjiSi D DE ©et, $WQ ID Nö: 28 szántó szekvenciáin €DR2:-í, •: és SEQ ID WÊCk 29 szerinti szskvsnerájá CDR! -et tartalmaz, vagy ásnák antigésikötő vagy immucologiailág ^működőképes mtónngtaható Eagrnantó© és olyan könnyűláncot, amely SEQ ID ND: i S szerinti szekvenciáié CDRi-et, SEQ ÍD NO: 16 szerinti szekvenciája ODRI-et, és SEQ ID NO: 17 szerinti s;mkvenetáp CDRI-et tartalmaz, vagy annak antigisfeSti vagy immuooiögiaiíag mőködöképes Immunglobulin ihigmensét, és ahol az ellenanyag gátolja a B7RPI aktivitást. %.·Μil* iglpypoäs#ssserb#eeBPtóyag» ától a nehézMpe a SEQ IPEIO: 7 vagy 8 szartól atónosav-SZekveaÄ latíaltetöó nebézlânc variábilis régiót tarlateáz, vagy mmk anEgétóStS vagy temunolteitóag működőképes immunglobulin iragmensét.
  2. 3. Az :L igénypont szerinti ellenanyag, ahol a könnyűlánc a SEQ ID NO: 1 szerinti amisosav-szekwnetó tstóímazó: feannyilánc variábilis régiót tteídmaz, vagy átósk atógtekító vagy temunsl^idiiag működőképes terma: globulin fragirtensét 4 Polipul«! amely tartalmazza a SEQ ID NO: 15, 16, 17, 27. 26 és 29 szerinti ammesav-szekvenciákat, ahol a polipepíkl specifikusait kötődik aB?RPÍ*hezés gátolja a B7RP1 aktivitást.
  3. 5, Az L Igénypont szedni izolált ellenanyag vagy ímgnmns, amely speetikusan tóttóik a SIRPldtó ától az ellenanyag kötődik a SBQ 10 NO : 6? szettet szekvenclitóz, de nem kötődik a B7RP1 extraeeteiáris iM^te lévő SEQ ID Mö: M szerinti .szekvenciához, és gátolja s B7RPÍ aktivitási & Izolál ellenanyag, anteiy speeiílknsan kötődik a B7RP:i4tez és verseng tr 87RP1 kötéséért a SBQ ID NO: I szerinti antinosav-szekvenslát tartalmazó könsyüiáne variábilis régiót és: SEQ ID NO: 7 vagy $ szettel amisosay-szekvenciát tartalmazó nehézláae variábilis régiót tartalmazó ellenanyagai, "iától az ellenanyag gátolja aB/RPi akiiivitast.
  4. 7. Az I:. igénypont szerinti ellenanyag, amely a. SBQ ID N'Q: 45 vagy· 46 szerte* amlnosav^szetóerisis, vagy annak antigénkötö vagy immunolögMiag működőképes immunglobulin Iragmense bármelyikét tartemazza.
  5. 8. Az I ,, S,: vagy 6. igénypont szerte! ellemtstyag, aboi a nehézlans és tóRiB#áse: egyláncá ellenanyag. 9. Â 8. igénypont szerinti ellenanyag. amely egyiáncú Fv ellenanyag. i& Az l ,r 5. vagy dl- igénypont szerinti ellenanyag, amely Fab ellenanyag. ti . Az: L, 5. vagy ?!, IgénypesR szerinti ellenanyag, amely Páb! ellenanyag. ti. Az 1., 5. vagy §L Igénypont szerinti1 ellenanyag,; amely ellenanyag. t !.. Az I,, 5, vagy 4 igénypont szerinti ellenanyag·.: ahol m ellenanyag teljesen tetei® ellen anyag.
  6. 14. Dydgyászaíl feészitmény, amely gyógyászattlag eliïsgaditatè hordozói és az 1., 5. vagy 6. igénypont szettet ellenanyag, vagy annak antígéntótö vagy tetmmoiögknlag működőképes temanglotólm tógntesse terápiásán hatásos mennyiséül tartalmazz. ÍS. Oyégyászati kite,Ítmény, amely t^ogyászafíiag iNíbpdteto hordozót és a 4. igénypont sznristi polipepíkl terápiásán hatásos mennyiségét tartalmazza. 118525-1581 LT E P ! 9 ! 5 398 B í 1., ;S.. vagy 6. pzeríÉÉ Oileomryag: vagy irágmense, gyégyszerkém történd alkalmazásra. 17.. Â.4.. Igénypont szerinti polipeptid, gvëgys&^kêat îirtésô áíkslmatfásrm
  7. 18.. Ax 1., 5. vagy 6. Ig§8$p0ßt sæm»ti ellenanyag, vagy annak nntigénkötÖ vagy lasí^uíiotógiaiag * működőképes temungídbA Imgmense, autoimmun betegség; vagy gpliadásos vélte pákítebeó történő kezelésében történő alkalmazásra, |§, á 4. jgátypeisí memM ellenanyag, wémimm betegség vagy gyulladásos válasz: páeiansöén történő kezelésében történő alkalmazásra. 2% M 1>, 5. vagy 4 igénypont szerinti: ellenanyag, vagy annak aniigénkötö vagy immunotogiallag működőképes limnonglbbale iragmense győgyászaiiag: hatásos mennyiségének alkalmazása B7RP1: Illat kêzveî antölmrnua: betegség vagy gytáiadSsos válasz: páeiensben történd kezelésére szolgáin gyógyszer slöáliitÉsázm 21. A 4. ígénypom szerinti poiipeptid gVégyásaattíag hatásos mennyiségének alkalmazása S7&PÍ által kőzvetílp aalsifßöiin betegség. vagy gyulladásos válasz páelansbeo történd kezelésére szolgáM; gyógyszer előállítására. 22, A 28, vagy 21, igénypont szerinti alkalmazás, áltól az; aaiosmmära betegség vagy gyulladásos, válasz ïmmtQié aÄttisz, asztma, Immao ímmbociiopéniás pazpnrá, sgyerözis multiple^, ^érbetegség, ö^oriázls, gyulladásos feétbeiegség, ©roka-ljetegság, íbkélyes wstagbé%yaiíadás, GtaveÁtempég, Itasymoio-téle pajzstóigyiyuiladis, vagy MsztQn& lugas erythematosus,
  8. 22, Az 1,, 5, vagy 6. igénypont szerinti ettermnyag* vagy annak amigéskötö vagy inmnmoiogisílag működőképes *mmtmgl;#eim fagmgnse gyógyászati tag hatásos mennyiségének alkáteazasa ko^tmaláeids szignál H-sejí aktiválást pámsasteí :^lo késziöoéoy előállítására, 24> E|áfás B7RP 1 detektálására biológiai mintában, amely eljárás magában íbgkija: aj a minta éntÂezteîését az S., 5, vagy 6, igénypontok bármelyike szerinti ellenanyaggal vagy & 4. i^ay|«nt szermii poilpe|ß3ddebo|yan ÂSlmënyek kbzöir, amelyek lehetővé teszik az ellenanyag: vagy polipeptid kötődését: a Sl/kPI-hez; és b) a megkötődött ellenanyag vagy pob|septid mennyiségétnek mérését a mioiábán, 2§, ölukieinsav-molekuia, amely 1,, 5, vagy 6. igénylőtök bármelyike szerinti ellenanyagot vagy 4. Igénypont szerinti polipepíldet kódot,
  9. 26. Izoláit nakleinsaynnelekola, amely á kővetkezők: által alkotott: esoporiboi kiválasztott anúnosav-xzekyeneiár iartalmazé polipeptideí kódol: faj SEQ ÍD NO: 1 és % fb) SEQ ID NO: 1 és 8, (ej SEQ 10 NO: 15, 16, 17, 27, 28, és 24, (d) SEQ !0 NO: 45 és ?. (e) SEQ ID NO: 45 és 8. és (!) SEQ 1D NO: ! és 46.
  10. 27. Öazdaseit, amely 25, vagy 24. igénypont szerinti nukiemsavMnolekulai tartalmaz,. 2®, ifcôîâft sejtvonai,, amely m I* % vagy 6. tgenypöntefc bármelyike szerinti ellenanyagot vagy 4, igénypont szerinti pollpepndet termek ^ 29. Pspressziós vekte., amely 25. yagy 26. igénypont szerinti aukkiosav-nookkulm tartalmaz,
  11. 39, Eljárás ôlfeîîïniyag víígy poiíppíid elöálMsára, amely «prés magában: taglalton 22. igénypont " szerinti gazdtojjt vagy a 2.Í. igénypont szádéit ss|tvöt5ál tenyésztéséi és az ellenanyag vagy poipeptiä bsgyipésér a tenyésztő tápközeghSI vagy a gazxkssp&ői 31. » Ellenanyag, amely SEQ IP isiö: 1 szerinti aonnesav-szifeeneiat tartalmazó kóanyóiáae variábilis pgstossSEQID NO: £ szerinti a®sa«--S2s^ssK3Â:'taîtitoa2ô· «étiézttoc vambils régiót fcœtaîesaz.
  12. 32. Ellenanyag., amely könnyüíáneot és nehézláncol tartalmaz, ahoí a könnyülánc SEQ ÈD Ä>: 1 tartalnsazó Mnnyölasa variábilis régiét és SEQ ID M3: 43 szerinti anánosav-saekvenept tartaton# könnyóline konstans régiót iartártnazy és álto a nehézlane SEQ ID HO: S szerinti atoasísav-székvéaeiát larpmazó nebézlte vtólbiEs régiót is SEQ IP W€& 41 szerinti aminesav-szekvaneiát laóatoaze nehézláne konstans régiót tartalmaz.
  13. 33. Ellenanyag, sntoy a SEQ lö NO: 45 szerint aminnsav-szekvenciából álló könnyóláncot és SEQ ÏD NO: 40 szermÉ stnatóssv-szekvénciáirói álló nehézltoeortartaíntaz.
HUE06787719A 2005-07-18 2006-07-18 Humán anti-B7RP1 semlegesítõ ellenanyagok HUE028830T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70026505P 2005-07-18 2005-07-18

Publications (1)

Publication Number Publication Date
HUE028830T2 true HUE028830T2 (hu) 2017-01-30

Family

ID=37562100

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE06787719A HUE028830T2 (hu) 2005-07-18 2006-07-18 Humán anti-B7RP1 semlegesítõ ellenanyagok

Country Status (26)

Country Link
US (4) US7868140B2 (hu)
EP (7) EP2388277A3 (hu)
JP (1) JP5142998B2 (hu)
KR (4) KR20140097582A (hu)
CN (1) CN101321783B (hu)
AU (1) AU2006270009A1 (hu)
BR (1) BRPI0614040B8 (hu)
CA (2) CA2854576A1 (hu)
CR (1) CR9745A (hu)
DK (1) DK1915398T3 (hu)
EA (1) EA021669B1 (hu)
ES (1) ES2572177T3 (hu)
HK (1) HK1120049A1 (hu)
HR (1) HRP20160875T1 (hu)
HU (1) HUE028830T2 (hu)
IL (6) IL188642A (hu)
MX (1) MX2008000734A (hu)
NO (1) NO345593B1 (hu)
NZ (2) NZ604090A (hu)
PL (1) PL1915398T3 (hu)
RS (1) RS54984B1 (hu)
SG (2) SG196835A1 (hu)
SI (1) SI1915398T1 (hu)
UA (1) UA102667C2 (hu)
WO (1) WO2007011941A2 (hu)
ZA (1) ZA200801137B (hu)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
DK2332978T3 (da) * 1999-02-03 2014-06-23 Amgen Inc Nye polypeptider, der er involveret ved et immunrespons
EP2388277A3 (en) * 2005-07-18 2013-03-20 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
MX2010002249A (es) * 2007-08-31 2010-03-17 Amgen Inc Formulacion de proteina de estado solido.
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
AR074438A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
WO2010064090A1 (en) * 2008-12-02 2010-06-10 Pierre Fabre Medicament Process for the modulation of the antagonistic activity of a monoclonal antibody
US8722046B2 (en) * 2009-04-08 2014-05-13 The United States Of America As Represented By The Secretary Of The Army Human monoclonal antibodies protective against bubonic plague
MX344382B (es) 2009-10-23 2016-12-14 Amgen Inc * Adaptador de vial y sistema.
WO2011156373A1 (en) 2010-06-07 2011-12-15 Amgen Inc. Drug delivery device
US8394378B2 (en) 2010-09-27 2013-03-12 Janssen Biotech, Inc. Antibodies binding human collagen II
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
US9480624B2 (en) 2011-03-31 2016-11-01 Amgen Inc. Vial adapter and system
EP2699293B8 (en) 2011-04-20 2022-07-20 Amgen Inc. Autoinjector apparatus
HUE043691T2 (hu) 2011-10-14 2019-09-30 Amgen Inc Befecskendezõ eszköz és összeszerelési eljárás
CN109022465B (zh) 2011-10-28 2022-04-29 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
EP4234694A3 (en) 2012-11-21 2023-09-06 Amgen Inc. Drug delivery device
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (ar) * 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
TWI639453B (zh) 2013-03-15 2018-11-01 美商安美基公司 用於注射器之匣盒
JP6336564B2 (ja) 2013-03-15 2018-06-06 アムゲン・インコーポレーテッド 薬物カセット、自動注入器、および自動注入器システム
TWI592183B (zh) 2013-03-15 2017-07-21 安美基公司 本體輪廓可調適之自動注射器裝置
EP2976117B1 (en) 2013-03-22 2020-12-30 Amgen Inc. Injector and method of assembly
EP3683312B1 (en) * 2013-04-23 2022-09-07 Elasmogen Limited Synthetic library of specific binding molecules
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
DK3677591T5 (da) 2013-04-29 2024-08-26 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antistoffer og fusioner til svækket interferon alpha-2b
AU2014318017B2 (en) 2013-09-05 2020-02-06 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
AU2014340171B2 (en) 2013-10-24 2019-05-30 Amgen Inc. Injector and method of assembly
EP3501575B1 (en) 2013-10-24 2021-12-01 Amgen Inc. Drug delivery system with temperature-sensitive-control
KR102446386B1 (ko) 2014-01-10 2022-09-22 아납티스바이오, 아이엔씨. 인터루킨-33 (il-33)에 대한 항체
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
RS59704B1 (sr) 2014-03-31 2020-01-31 Univ I Tromsoe Norges Arktiske Univ Antitela protiv hpa-1a
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
MX2016014561A (es) 2014-05-07 2017-06-21 Amgen Inc Autoinyetor con elementos reductores del shock.
AU2015259053B2 (en) 2014-05-16 2020-12-24 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
MX2016015854A (es) 2014-06-03 2017-07-19 Amgen Inc Sistema de suministro de farmacos controlable y metodo de uso.
EP3943135A3 (en) 2014-10-14 2022-06-29 Amgen Inc. Drug injection device with visual and audible indicators
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
PE20170908A1 (es) 2014-10-29 2017-07-12 Teva Pharmaceuticals Australia Pty Ltd VARIANTES DE INTERFERON a2b
ES2785311T3 (es) 2014-12-19 2020-10-06 Amgen Inc Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
EP3233163B1 (en) 2014-12-19 2021-10-13 Amgen Inc. Drug delivery device with proximity sensor
WO2016133947A1 (en) 2015-02-17 2016-08-25 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
JP2018512184A (ja) 2015-02-27 2018-05-17 アムジエン・インコーポレーテツド 針ガードの移動に対する抵抗力の閾値が調整可能な針ガード機構を備えた薬物送達装置
ITUB20151014A1 (it) 2015-05-27 2016-11-27 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
CR20180234A (es) 2015-11-03 2018-09-11 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
EP3386573B1 (en) 2015-12-09 2019-10-02 Amgen Inc. Auto-injector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
AU2017250358B2 (en) 2016-04-15 2023-06-01 Alpine Immune Sciences, Inc. ICOS ligand variant immunomodulatory proteins and uses thereof
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (es) 2016-05-13 2019-02-21 Amgen Inc Montaje de cubierta protectora de vial.
EP3458988B1 (en) 2016-05-16 2023-10-18 Amgen Inc. Data encryption in medical devices with limited computational capability
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
EP3515489A4 (en) * 2016-09-19 2020-05-06 Oncoimmune, Inc. CD80 AND CD86 BINDING PROTEIN COMPOSITIONS AND USES THEREOF
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
JP2020503976A (ja) 2017-01-17 2020-02-06 アムジエン・インコーポレーテツド 注入デバイスならびに関連する使用および組立方法
AU2018221351B2 (en) 2017-02-17 2023-02-23 Amgen Inc. Insertion mechanism for drug delivery device
EP3582825A1 (en) 2017-02-17 2019-12-25 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
JP2020508803A (ja) 2017-03-06 2020-03-26 アムジエン・インコーポレーテツド 作動防止特徴部を備える薬物送達デバイス
AU2018230546B2 (en) 2017-03-07 2024-03-21 Amgen Inc. Needle insertion by overpressure
US11986624B2 (en) 2017-03-09 2024-05-21 Amgen Inc. Insertion mechanism for drug delivery device
JP2020513813A (ja) 2017-03-14 2020-05-21 アムジエン・インコーポレーテツド 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
DK3600491T3 (da) 2017-03-28 2023-10-23 Amgen Inc Stempelstang og sprøjtekonstruktionssystem samt fremgangsmåde
MX2019014615A (es) 2017-06-08 2020-02-07 Amgen Inc Dispositivo de administracion de farmacos accionado por par de torsion.
EP3634539A1 (en) 2017-06-08 2020-04-15 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
WO2018236619A1 (en) 2017-06-22 2018-12-27 Amgen Inc. REDUCING THE IMPACTS / IMPACTS OF ACTIVATION OF A DEVICE
US11395880B2 (en) 2017-06-23 2022-07-26 Amgen Inc. Electronic drug delivery device
EP3651832B1 (en) 2017-07-14 2023-12-13 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
US11672733B2 (en) 2017-07-21 2023-06-13 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
EP3658206A1 (en) 2017-07-25 2020-06-03 Amgen Inc. Drug delivery device with container access system and related method of assembly
EP4085942A1 (en) 2017-07-25 2022-11-09 Amgen Inc. Drug delivery device with gear module and related method of assembly
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
EP3691717B1 (en) 2017-10-04 2023-02-08 Amgen Inc. Flow adapter for drug delivery device
ES2971450T3 (es) 2017-10-06 2024-06-05 Amgen Inc Dispositivo de administración de fármacos con conjunto de enclavamiento y procedimiento de montaje correspondiente
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
US11305026B2 (en) 2017-11-03 2022-04-19 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
WO2019090303A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Fill-finish assemblies and related methods
EP3706830B1 (en) 2017-11-06 2024-08-07 Amgen Inc. Drug delivery device with placement and flow sensing
CA3079665A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
MA50903A (fr) 2017-11-16 2021-05-12 Amgen Inc Auto-injecteur avec détection de décrochage et de point d'extrémité
JP7370969B2 (ja) 2017-11-16 2023-10-30 アムジエン・インコーポレーテツド 薬物送達デバイスの扉ラッチ機構
JP2021519068A (ja) 2018-03-26 2021-08-10 アムジェン インコーポレイテッド 細胞培養において産生される抗体の総非フコシル化グリコフォーム
AU2019250882A1 (en) 2018-04-12 2020-11-05 Amgen Inc. Methods for making stable protein compositions
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
MA53375A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
US12115360B2 (en) 2018-07-24 2024-10-15 Amgen Inc. Hybrid drug delivery devices with grip portion
US12042645B2 (en) 2018-07-24 2024-07-23 Amgen Inc. Delivery devices for administering drugs
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
CA3103105A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
JP2022500095A (ja) 2018-09-24 2022-01-04 アムジエン・インコーポレーテツド インターベンション投薬システム及び方法
IL281469B2 (en) 2018-09-28 2024-08-01 Amgen Inc Assembling a memory alloy ejector activation assembly for a drug delivery device
WO2020072577A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
MA53818A (fr) 2018-10-05 2022-01-12 Amgen Inc Dispositif d'administration de médicament ayant un indicateur de dose
AR116704A1 (es) 2018-10-15 2021-06-02 Amgen Inc Dispositivo de administración de fármacos con mecanismo de amortiguación
EA202191038A1 (ru) 2018-10-15 2021-07-06 Эмджен Инк. Способ платформенной сборки для устройства доставки лекарственного средства
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
AU2019370159A1 (en) 2018-11-01 2021-04-22 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
MX2021012557A (es) 2019-04-24 2021-11-12 Amgen Inc Conjuntos y metodos de verificacion de esterilizacion de jeringuillas.
WO2021041067A2 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
US20220349898A1 (en) 2019-09-26 2022-11-03 Amgen Inc. Methods of producing antibody compositions
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CN111925442B (zh) * 2020-08-19 2022-10-11 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
MX2023004364A (es) 2020-10-15 2023-05-03 Amgen Inc Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
US20240208680A1 (en) 2021-05-21 2024-06-27 Amgen Inc. Method of optimizing a filling recipe for a drug container
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4912040A (en) * 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
US5151510A (en) * 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
EP0590076A4 (en) 1991-06-14 1997-02-12 Dnx Corp Production of human hemoglobin in transgenic pigs
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US7435796B1 (en) * 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
DK2332978T3 (da) * 1999-02-03 2014-06-23 Amgen Inc Nye polypeptider, der er involveret ved et immunrespons
CN101066997B (zh) 1999-03-25 2013-03-27 艾博特股份有限两合公司 结合人il-12的人抗体及其生产方法
DE60037896D1 (de) 1999-07-29 2008-03-13 Medarex Inc Menschliche antikörper gegen her2/neu
US6984720B1 (en) * 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
EP1218504B1 (en) * 1999-09-21 2007-07-11 Genetics Institute, LLC Gl50 molecules and uses therefor
GB0016633D0 (en) 2000-07-07 2000-08-23 Bp Exploration Operating Process
WO2002044364A2 (en) * 2000-11-28 2002-06-06 Amgen Inc. Polypeptides involved in immune response
WO2004043989A2 (en) 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
ATE455127T1 (de) 2003-05-31 2010-01-15 Micromet Ag Humane anti-humane cd3-bindungsmoleküle
US7271245B2 (en) * 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
WO2006003999A1 (ja) * 2004-07-05 2006-01-12 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ヒト抗ヒトb7rp-1抗体およびその抗体フラグメント
EP2388277A3 (en) * 2005-07-18 2013-03-20 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
WO2013180295A1 (ja) 2012-06-01 2013-12-05 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
KR20100101016A (ko) 2010-09-15
EA200800355A1 (ru) 2008-08-29
KR20130023356A (ko) 2013-03-07
ZA200801137B (en) 2010-05-26
EP2388277A3 (en) 2013-03-20
US9266945B2 (en) 2016-02-23
IL218889A0 (en) 2012-05-31
BRPI0614040A2 (pt) 2011-03-09
EP2388276A3 (en) 2013-11-27
IL218890A0 (en) 2012-05-31
NO20080302L (no) 2008-04-15
SG164369A1 (en) 2010-09-29
IL188642A (en) 2015-01-29
EP2397498A2 (en) 2011-12-21
EP1915398B1 (en) 2016-04-20
CA2614972C (en) 2014-08-19
NO345593B1 (no) 2021-05-03
IL218888A0 (en) 2012-05-31
HK1120049A1 (zh) 2009-03-20
NZ604090A (en) 2014-07-25
KR101024758B1 (ko) 2011-03-24
DK1915398T3 (en) 2016-07-04
WO2007011941A3 (en) 2007-05-03
EP2397499A3 (en) 2013-12-25
KR20080049014A (ko) 2008-06-03
CA2854576A1 (en) 2007-01-25
EP2397496A2 (en) 2011-12-21
CN101321783B (zh) 2015-08-26
JP2009501549A (ja) 2009-01-22
BRPI0614040B8 (pt) 2021-05-25
BRPI0614040B1 (pt) 2020-02-04
HRP20160875T1 (hr) 2016-09-23
EP2388276A2 (en) 2011-11-23
US10072090B2 (en) 2018-09-11
IL218892A0 (en) 2012-05-31
CR9745A (es) 2008-07-22
EP2397499A2 (en) 2011-12-21
PL1915398T3 (pl) 2016-10-31
EP2397497A3 (en) 2013-11-27
CA2614972A1 (en) 2007-01-25
SG196835A1 (en) 2014-02-13
US8981071B2 (en) 2015-03-17
CN101321783A (zh) 2008-12-10
EA021669B1 (ru) 2015-08-31
US7868140B2 (en) 2011-01-11
IL218893A0 (en) 2012-05-31
UA102667C2 (uk) 2013-08-12
WO2007011941A9 (en) 2008-02-21
EP2397497A2 (en) 2011-12-21
EP1915398A2 (en) 2008-04-30
WO2007011941A2 (en) 2007-01-25
US20130171695A1 (en) 2013-07-04
RS54984B1 (sr) 2016-11-30
US20080166352A1 (en) 2008-07-10
EP2397498A3 (en) 2013-11-27
JP5142998B2 (ja) 2013-02-13
KR101263079B1 (ko) 2013-05-09
AU2006270009A1 (en) 2007-01-25
US20160145345A1 (en) 2016-05-26
MX2008000734A (es) 2008-03-19
US20110104757A1 (en) 2011-05-05
EP2388277A2 (en) 2011-11-23
EP2397496A3 (en) 2013-05-29
SI1915398T1 (sl) 2016-07-29
KR20140097582A (ko) 2014-08-06
IL188642A0 (en) 2008-04-13
ES2572177T3 (es) 2016-05-30
NZ625807A (en) 2015-11-27

Similar Documents

Publication Publication Date Title
US10072090B2 (en) Human anti-B7RP1 neutralizing antibodies
KR101329843B1 (ko) Ｃｄ25에 대한 인간 모노클로날 항체
JP5466691B2 (ja) Ｉｐ−１０抗体およびその用途
AU2003286437A1 (en) HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
CA2481074A1 (en) Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
AU2017200408B2 (en) Human anti-B7RP1 neutralizing antibodies
AU2011265342B2 (en) Human anti-B7RP1 neutralizing antibodies